GTN

company

About

GTN innovates a quantum machine learning technology to transform drug discovery.

  • 1 - 10

Details

Last Funding Type
Non-Equity Assistant
Industries
Biotechnology,Chemical,Machine Learning,Quantum Computing
Founded date
May 17, 2017
Number Of Employee
1 - 10
Operating Status
Active

Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years.

At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
£2.10M
GTN has raised a total of £2.10M in funding over 2 rounds. Their latest funding was raised on May 4, 2018 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 4, 2018 Seed £2.10M 1 Octopus Ventures Detail
Jun 1, 2017 Non-Equity Assistant 1 Google for Startups Detail

Investors

Number of Lead Investors
Number of Investors
2
2
GTN is funded by 2 investors. Octopus Ventures and Google for Startups are the most recent investors.
Investor Name Lead Investor Funding Round
Octopus Ventures Yes Seed
Google for Startups Yes Non-Equity Assistant